Updated from 11:46 a.m. EST

Earnings Reports & Outlooks


(BVSN) - Get Report

said after the close Monday that it expects revenue for the first quarter of $29 million to $32 million. According to First Call, analysts expect a top line of $35.6 million. In the same quarter a year ago, revenue totaled $91.1 million. Additionally, Broadvision restated its financial results for the third quarter and fourth quarter of fiscal 2001, along with its financials for the full year 2001. As a result of the changes, revenue for the third quarter decreased by $3.5 million to $47.7 million, and the pro forma and actual loss widened by a penny. Revenue for the fourth quarter increased by $251,000 to $48.2 million. The fourth-quarter pro forma loss wasn't changed, but the reported loss narrowed by a penny. For fiscal 2001, revenue decreased by $3.3 million to $244.5 million, while the pro forma loss and the actual loss widened by 1 cent. Shares of Broadvision were falling 13.4% to $1.49.

Enterprise Products Partners

(EPD) - Get Report

expects to report a first-quarter loss of 20 cents to 25 cents per partnership unit because of losses resulting from the company's natural gas hedging activities. Analysts expect a profit of 63 cents. Shares of Enterprise, a natural gas services partnership, were down 5.5% to $46.


(LMNX) - Get Report

expects first-quarter revenue of $2.2 million to $2.7 million and a loss of 20 cents to 23 cents a share. The company also expects revenue for the full year to fall below its previous guidance of $35 million to $40 million. Analysts expect a first-quarter loss of 17 cents and revenue of $4.6 million. For the year, Wall Street is looking for a top line of $32 million. Shares of Luminex were plunging 34.6% to $7.48.

Russell Corp.


expects to report first-quarter earnings of 6 cents to 8 cents a share on sales of $214 million to $217 million. For the second quarter, the maker of casual and athletic clothing expects to earn 14 cents to 18 cents a share, excluding charges but including a gain. Sales for the second quarter should be $254 million to $262 million. Russell forecast earnings of $1.45 to $1.60 a share for 2002, with sales of $1.18 billion to $1.22 billion. Analysts expect the company to post first-quarter earnings of 5 cents, second-quarter earnings of 10 cents and full-year earnings of $1.45. The stock was up 12.8% to $16.60.



expects to earn 4 cents to 5 cents a share, excluding certain items, in the March quarter, while revenue should rise 30% sequentially. Analysts expect the company to earn a penny. The forecast sent the stock up 8.8% to $9.32, breaking through the old 52-week high.

Mergers, Acquisitions & Joint Ventures



was rising 11.9% to $7.05 following a report in the

Financial Times




might be considering retaking full control of the electronic trading operation. Reuters owns about 83% of Instinet. The report also said Reuters might be considering selling Instinet or merging it with another electronic broker.

Miscellaneous News


(ACAM) - Get Report

said the recent discovery by



of 70 million to 90 million doses of smallpox vaccine doesn't affect its existing agreement to deliver 209 million doses of smallpox vaccine to the U.S. Centers for Disease Control. Aventis found the vaccine last week and offered to donate the supply to the U.S. Acambis was up 8.9% to $46.37.



said the Securities and Exchange Commission plans to recommend an enforcement action against the company, along with certain former officers and a current employee. The company said the recommended actions concern alleged misstatements, in quarterly and annual SEC filings and press releases, of its income for fiscal year 2000. Akorn disagrees with the allegations and plans to offer its opinion to the SEC as to why an enforcement action shouldn't be brought against the company. Akorn was off 5.6% to $3.52.

Noven Pharmaceuticals

(NOVN) - Get Report

said after the close Monday that its MethyPatch, a treatment for attention deficit hyperactivity disorder, was effective in a late-stage clinical trial. The company plans to file a new drug application for the patch with the Food and Drug Administration in the middle of the year. The stock rose in extended-session trading Monday and was recently higher by 6.6% to $21.31.

Stillwater Mining


said the Securities and Exchange Commission is questioning the company's methodology for calculating its probable ore reserves. The company, which mines metals in the platinum group, said its proven reserves aren't affected by the SEC's concerns. The SEC believes the company's methods for determining probable reserves should be revised in order to conform with the agency's interpretation of industry standards, but Stillwater plans to "vigorously defend" its calculations. If the company is unable to convince the SEC that its calculations are accurate, it could be forced to restate certain prior-year results. The stock was dropping 22.1% to $14.51.